Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis
News Aug 29, 2013
Lipidor has announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO®/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis. Karolinska Development owns 50% of Lipidor.
“The positive study results represents an important milestone for Lipidor in its efforts to develop a product with equivalent clinical efficacy compared to market leading calcipotriol-only topical treatments, and with superior cosmetic qualities and greater ease of use, thereby, improving compliance rates and patient quality of life”, concludes Anders Carlsson, CEO of Lipidor.
Various kinds of ointments, creams and lotions are commonly prescribed treatments for psoriasis, but they also show low compliance rates.
This is largely due to their greasiness and inability to absorb into the skin and therefore be present on the skin for a long time after application. This causes personal discomfort as well as staining of clothes.
Lipidor is developing AKVANO®/calcipotriol, a water-free spray formulation containing calcipotriol, a vitamin D derivative that is one of the cornerstones in the treatment of mild to moderate psoriasis vulgaris.
The AKVANO® technology enables efficient delivery of the pharmaceutical ingredient. After application the carrier compounds evaporates quickly, leaving a pleasant feeling on the skin and a cosmetically appealing result.
Data from the recently concluded Phase I/IIa clinical study in 24 psoriasis vulgaris patients revealed that the AKVANO®/calcipotriol spray formulation had clear and significant antipsoriatic effects compared to placebo, comparable to a marketed formulation of calcipotriol. This means that the primary objective of the trial was met.
In the study, the patients received 10 topical treatments over 12 days. No safety issues were noted in the study. Approximately 125 million patients suffer from psoriasis worldwide.
While the disease varies in its manifestation, psoriasis vulgaris that affects 80-90% of the patients typically causes plaques of rapid skin accumulation at certain areas of the skin.
One of the measures of disease severity is the body surface area covered by affected skin plaques or lesions, from distinctly localized to widespread. Psoriasis can cause itching and pain, scaling of skin and bleeding lesions.
Quality of life aspects, including self-consciousness and social withdrawal are important factors in the management of the disease including treatment compliance.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018